Asston Pharmaceuticals' IPO is scheduled to open on July 9, 2025, and will close on July 11, 2025. This is a Book Build Issue through which the company aims to raise approximately ₹27.56 crores. The offering includes a fresh issue worth ₹27.56 crores along with an offer for sale of equity shares with a face value of ₹10 each.

The price band for the IPO is set between ₹115 and ₹123 per share. The quota distribution is 35% for retail investors, 50% for qualified institutional buyers (QIBs), and 15% for high net-worth individuals (HNIs). The allotment is expected to be finalized on July 14, 2025, and the shares are likely to be listed on the BSE on July 16, 2025.

In terms of financial performance, the company recorded revenue of ₹25.61 crores in 2025, up from ₹15.84 crores in 2024. Net profit also increased to ₹4.33 crores in 2025 compared to ₹1.36 crores in 2024. Based on this strong financial growth, the IPO is considered a good option for long-term investors.

About Asston Pharmaceuticals IPO

Asston Pharmaceuticals Pvt. Ltd. is a leading pharmaceutical company, founded in 2019 by its promoters Dr. Ashish Sakalkar, Mrs. Saili More, and Mr. Sachin Badakh. Together, they bring over 25 years of experience in the pharmaceutical industry, particularly in the export of healthcare products to various international markets. The company supplies pharmaceutical and healthcare products in multiple forms, including tablets, capsules, sachets, and syrups.